Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. - Wikidata - wikimedia - TriplyDB

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

http://www.wikidata.org/entity/Q33984182

about

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection GagCM9-specific CD8+ T cells expressing limited public TCR clonotypes do not suppress SIV replication in vivo Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).HIV-1 vaccine clinical trials: the Brazilian experience.HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge New directions for HIV vaccine development from animal models.Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.No acquisition: a new ambition for HIV vaccine development?Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 va A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge Replicating and non-replicating viral vectors for vaccine development Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses Problems and emerging approaches in HIV/AIDS vaccine development.Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?GagPol-specific CD4⁺ T-cells increase the antibody response to Env by intrastructural help.Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.Animal models in virus research: their utility and limitations.Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.Increased mucosal CD4+ T cell activation in rhesus macaques following vaccination with an adenoviral vector.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development

P2860

Q24652185-D7C795D4-4DF1-4BAD-A408-BD74EDE01808 Q26775082-C9A249F8-61A6-4DB6-8D7B-C0FC34B5DDEE Q27324128-7A69360A-2063-4A72-B372-10669BD8B7E1 Q28972526-EA6762C1-638C-42F8-A97E-971573B6E9F4 Q30379200-B3D899FF-F94E-4EF0-BD2F-6F747F615DA9 Q30379462-38B67A0E-FF7A-49EC-B0EB-685A54A58CAE Q30381447-0DBCB20D-5623-4B71-B286-88A65E614309 Q33676444-0CA3C949-30B8-4A82-8230-C2BDB94D9F88 Q33767191-030E7693-AB68-44CF-83E3-61CF2F62A7D3 Q33992829-C864596D-F447-467D-B491-65C2D92E05B4 Q34075166-0E1661FD-FC65-4304-8DC9-E1ECF847EED2 Q34488930-7331E76C-EC3B-4A59-995A-C6B09C7D6968 Q34514374-BA4D48A4-4633-4291-9C80-A53A55BC7480 Q34546037-49F14871-86DB-43FF-880A-D9876FC3A3D4 Q34632979-9C83581B-60A1-4A3F-8160-418FFFE16504 Q34756847-E001317C-F155-47DF-929F-3BE5FACA73A2 Q35024266-9609E3A5-6F56-46FC-A1B9-97A1CEF576DE Q35049812-54A3439F-ED9F-4C3C-A425-0582977F6EBC Q35534563-011C25B9-65B8-4FC3-8860-09A59D28871C Q35636394-C592C3D2-7AF6-47B8-96AE-8B2529F0A4C9 Q35785031-2B64748A-9AAA-473F-AB82-91D12B4B49BE Q35826525-44FC8B37-D7B9-4811-A6AB-D70B85A5D4E7 Q36024470-E1955ED9-0BE8-419C-ACFE-DA90D5E4F57A Q36464587-CEF6E041-50EA-461E-A3F6-486D5CFA31C5 Q36498186-E1FDB15D-83BF-44B5-923D-4C08B8693D8E Q36736860-700DAF51-80CA-471A-940D-7DB2472ED829 Q36758574-FEE802E9-5FD9-44C2-9892-7EF4DE5B1773 Q37215858-7B811351-6880-483B-80B6-1CA53C18F0A3 Q37220038-774DF138-C314-428B-80C1-C86969BBE24A Q37418439-917F9593-836E-4D1C-8F31-9CBB9F77FA1A Q37785947-6D13DE27-A7DC-4218-B10E-1FAF1748FD13 Q38043556-C7A89E66-ADF6-4C01-885A-204D0E9A1DE4 Q39992443-CAFE2B8C-86EF-4108-A246-42A832CBD8A2 Q40548641-FC333A06-3ADA-4D7F-A4F2-69F1EED3C4B0 Q41838022-3132C870-B140-464F-BE25-DC92F7EA7DE6 Q56993265-B3FB8B33-823D-4E5C-982C-FD54E0B47AC6

P2860

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

http://www.wikidata.org/entity/Q33984182

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Vectored Gag and Env but not T ...... -A*01-negative rhesus monkeys.

@ast

Vectored Gag and Env but not T ...... -A*01-negative rhesus monkeys.

@en

type

label

Vectored Gag and Env but not T ...... -A*01-negative rhesus monkeys.

@ast

Vectored Gag and Env but not T ...... -A*01-negative rhesus monkeys.

@en

prefLabel

Vectored Gag and Env but not T ...... -A*01-negative rhesus monkeys.

@ast

Vectored Gag and Env but not T ...... -A*01-negative rhesus monkeys.

@en

P1433

Q33984182-DC829228-981E-49E3-A045-B3D90E9860A9

P1476

Q33984182-598ADE64-4F1E-434E-AA93-6C7C5D06E4F4

P2093

Q33984182-02ABD37E-FA46-4913-AC4B-E03C826C6481

Q33984182-0D04573A-63F7-4E18-8623-282D6BEE5009

Q33984182-177A2DAC-D3CE-4730-ACE9-1F56610A2CB1

Q33984182-18F1CBAC-B1B7-4D77-BB99-AA8C2F25B51A

Q33984182-1B080DCF-7EEA-4182-818A-D753A83DEE41

Q33984182-24CD4A70-663D-429C-86D0-CD3A42406298

Q33984182-26CC4AF3-BB64-49D2-A9FE-551F2DC3C85A

Q33984182-5BC2DA51-586A-4AFB-9C8F-A00F1EC2F336

Q33984182-65D9DB28-3800-4FA8-BA89-9E97C5B83FAD

Q33984182-6A6B1845-8378-4C72-9575-2ED00F357921

P2860

Q33984182-049B862B-366D-42B5-AFDF-ADA7B1245A6B

Q33984182-05A49B8B-A824-432D-B89F-407BD8A4EE7F

Q33984182-087A51BA-103A-4C5F-B96F-4415689DC791

Q33984182-089E0EF0-C9F7-47C5-98BB-2A1757791170

Q33984182-103B53DB-4B3D-4FC5-8B4E-292662B258E4

Q33984182-11660127-5D83-4E3B-B904-DF551159B84C

Q33984182-35899E2B-68B6-46E5-A6FD-9E6FBCBCF713

Q33984182-366C8C46-CCAB-4581-AED0-8D91C3B5877C

Q33984182-38336518-2432-4AE8-8EF9-29B219877F35

Q33984182-400097C0-6770-40EB-86F2-8ACEDEDA3FA1

P304

Q33984182-361578D0-5EEB-4DA3-8F8C-611398DFEFA3

P31

Q33984182-C9C79F42-3774-4AB8-8513-BFD6DFF8DFF9

P356

Q33984182-A43AB4B4-D458-4F37-A8C7-74F79BD62A09

P407

Q33984182-22C10F17-986B-40E5-9D1B-0D7E6C571183

P433

Q33984182-51895D2A-F3A4-4F25-A14F-A82130F171FB

P478

Q33984182-47D1E335-8DF0-494D-94C4-7C0E3B789C07

P577

Q33984182-83FF9CCA-F971-4C3B-83A7-8E86F420ED16

P698

Q33984182-9C40EFD1-4B2D-4384-8E48-C7780E5793A3

P921

Q33984182-B1D85196-AA66-4512-9E1A-604FEA1091EA

P932

Q33984182-10980F52-4CF6-49C5-98FF-99A05FED2FD1

P356

JVI.79.19.12321-12331.2005

P1433

Journal of Virology

P1476

Vectored Gag and Env but not T ...... -A*01-negative rhesus monkeys.

@en

P2093

Adam C Finnefrock

http://www.w3.org/2001/XMLSchema#string

Aimin Tang

http://www.w3.org/2001/XMLSchema#string

Anthony Carella

http://www.w3.org/2001/XMLSchema#string

Cheryl Moyer

http://www.w3.org/2001/XMLSchema#string

Danilo R Casimiro

http://www.w3.org/2001/XMLSchema#string

Deepa Patel

http://www.w3.org/2001/XMLSchema#string

Emilio A Emini

http://www.w3.org/2001/XMLSchema#string

Fubao Wang

http://www.w3.org/2001/XMLSchema#string

Gwendolyn Heidecker

http://www.w3.org/2001/XMLSchema#string

Jing Lin

http://www.w3.org/2001/XMLSchema#string

P2860

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

Antibody neutralization and escape by HIV-1

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

P304

12321-12331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.79.19.12321-12331.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16160159

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

1211517

http://www.w3.org/2001/XMLSchema#string